Zoetis (ZTS)

The sleeper story isn't the guidance cut everyone will headline tonight, it's that Zoetis is defending share through an unquantified rebate mechanism management openly admits investors can't see, while the price/volume breakdown that used to let us sanity-check demand simply disappeared from the script. The obvious headline, 'guidance flipped from +2-5% growth to a 1-3% decline', is real and ugly, but the more important read is that livestock, the offset that made the diversified-portfolio thesis work, is itself guided down and partly transitory, just as companion animal deteriorates further (derm -18% in the US, worse than Q1's -13%). The binding constraint isn't product differentiation or pipeline (12 blockbusters, unchanged narrative), it's commercial/pricing visibility: management's own words, 'Is that 12 or 18 months? I can't tell you', tell you they don't know when this stabilizes. My view changes if Zoetis discloses a quantified gross-to-net rate (even a range) next quarter and if US in-clinic share data (independently verified) shows actual stabilization rather than management's self-reported framing.